Novartis (NYSE:NVS) has launched its Ultibro Breezhaler and Seebri Breezhaler in China for the treatment of chronic obstructive pulmonary disease.
The Ultibro Breezhaler system is a once-daily fixed-dose combination of indacaterol and glycopyrronium bromide. Seebri Breezhaler is a fixed-dose formulation of glycopyrronium bromide.
Get the full story at our sister site, Drug Delivery Business News.
The post Novartis launches COPD inhalers in China appeared first on MassDevice.
from MassDevice https://ift.tt/2YgTDvu
Cap comentari:
Publica un comentari a l'entrada